Journal of Preventive Cardiology
spacer
Current Issue

State-of-the-art-article

Year: 2016 I  Volume: 6I  Issue: 1I  Pages:947–953
 

Familial hypercholesterolemia - An underdiagnosed and undertreated entity

Dr. J P S Sawhney*, DM; Sourabh Bagga†, DM; Simran Sawhney‡, MBBS

*Chairman, Department of Cardiology, Dharma Vira Heart Centre, Sir Ganga Ram hospital, New Delhi-110060, India

†Senior Resident, Department of Cardiology, G B Pant Hospital, New Delhi

‡ Post Graduate Medicine, St. Stephen Hospital, Delhi -110054

 

Abstract

Familial hypercholesterolemia (FH) is a common autosomal-dominant disorder characterized by a raised level of low-density lipoprotein cholesterol (LDL-C) and a high risk of premature coronary heart disease (CHD). Diagnosis of FH largely relies on the evaluation of LDL-C levels, a careful documentation of family history, and the identification of clinical features. FH is underdiagnosed and undertreated, with only 1% being treated even in developed nations.

The primary goal for the treatment of FH is to reduce mortality and atherosclerotic cardiovascular disease events, which is achieved by reducing plasma LDL levels. European Society of Cardiology (ESC) guidelines recommend LDL goal of 70-100 mg/dL depending on associated cardiovascular disease risk. Statins are presently the mainstay in the management of these patients. A substantial population of patients cannot take advantage of statin therapy as they do not reach LDL goal despite using maximum tolerated doses or due to statin intolerance, suggesting a need for additional effective agents to reduce LDL-C levels. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors such as evolocumab and alirocumab are newer treatment options which provide additional options to further lower LDL levels. Evolocumab and alirocumab are fully human monoclonal immunoglobulin G2 (IgG2) directed against human PCSK9. By inactivating PCSK9, they upregulate LDL receptors, thereby increasing catabolism of LDL-C and consequently reducing LDL-C levels in blood.

In this article, we review FH, complexity of diagnosis and management, and newer treatment options like PCSK9 inhibitors that could help improve the management of FH.

 
Keywords
Familial hypercholesterolmia
LDL-cholesterol
Statin Therapy
Evolocumab
 
[Full Text]
Print this Article
Back to main page
Slideshow
  • State-of-the-Art Article
    Heart Failure in India
    -Dr. Sandeep Seth, MD, DM.
    abstract text full text
  • Original Article
    Prediction of Coronary Heart Disease Development Using Risk Assessment Chart
    -Hassan Farag*,ƚ, DrPH; Ekram W. Abd El-Wahab*, PhD; Ashraf Yehia*, DPH
    abstract text full text
  • Original Article
    Effect of Macronutrients on Blood Pressure in Young Adult Men
    -Dr Pushpa Krishnaiǂ, MBBS; Dr. Abhishek M*, MBBS; Dr. Pushpa Krishnai, MD
    abstract text full text
  • Case Study
    A Case of Mobile Apical Thrombus in a Patient of NSTEMI
    -Dr. Mohit Singh Tandon*, MD Medicine, Diploma Echocardiography; Dr. Vineeta Singh* MD Medicine
    abstract text full text
  • Updates on Statins
    full text
  • Updates on Guidelines
    full text
  • News and Views
     
    full text
spacer
Slideshow
  • 11th Asia Pacific Heart Rhythm Society Scientific Session (APHRS 2018)
    To be held on October 17-20, 2018, Taipei, Taiwan
    Read more...
  • Catheter Interventions in Structural, Valvular and Congenital Heart Disease, Atrial Fibrillation and Heart Failure - UCSF 2018 (CSI - UCSF 2018)
    To be held on October 26 – 27, 2018, San Francisco, USA
    Read more...
  • RCPE Symposium: Cardiology 2018
    To be held on November 2, 2018, Edinburgh, United Kingdom
    Read more...
  • The Heart Course 2018
    To be held on November 5-8, 2018, Las Vegas, United States
    Read more...
  • American Heart Association Scientific Sessions 2018 (AHA 2018)
    To be held on November 10- 12, 2018, Chicago, United States
    Read more...
  • 70th Annual Conference of Cardiological Society of India CSI 2018
    To be held on November 22-25, 2018, Mumbai, India
    Read more...
  • World Heart Federation World Congress of Cardiology & Cardiovascular Health 2018 (WHF 2018)
    To be held on December 5-8, 2018, Dubai, United Arab Emirates
    Read more...
  • Device Therapies for Heart Failure 2018 (D-HF 2018)
    To be held on December 14-15, 2018, Frankfurt Am Main, Hessen, Germany
    Read more...
Journal of Preventive Cardiology
spacer
 
spacer
Print ISSN: 2249-4308
Online ISSN: 2277-6559
 
Frequency: Quarterly
 
 
Email This
close
 
 
  [ Separate multiple email addresses with commas (Limit is 10). ]